ALKBH5 and prostate cancer: The result has shown that gene-level deletion of YTHDF3 (HR 0.42, 95% CI 0.19-0.95), FTO (HR 0.57 95% CI 0.35-0.9) and amplification of ALKBH5 (HR 2.48 95% CI 1.39-2.42) were risk factors of prostate cancer biochemical recurrence (Figure 8G).